Money

Apontis Pharma (APPH): Initiation - A phoenix rises

Friday, May 14, 2021 - 8:00am

b"Apontis Pharma is a speciality pharma business aiming to leverage its commercial heritage in Germany and deliver on its rapid growth ambitions.

Key Points: 
  • b"Apontis Pharma is a speciality pharma business aiming to leverage its commercial heritage in Germany and deliver on its rapid growth ambitions.
  • Alongside the 'single pill strategy', Apontis also has co-marketing agreements for several branded drugs (2020 sales of \xe2\x82\xac16.6m).
  • It is the increasing mix of the higher-margin single pills that we believe should benefit current operating leverage and provide the foundations for an enticing margin story.
  • Edison's reports are not solicitations to buy or sell any securities.\nLearn more at www.edisongroup.com and connect with Edison on:\n"

CoinZoom Joins Visa's Fintech Fast Track Program

Friday, May 14, 2021 - 7:00am

Through its latest collaboration with Visa to integrate Visa Direct, Visa\'s real-time push payments platform, and participation in the Fintech Fast Track program, the company is launching an innovative service for all customers, called CoinZoom Instant.\nWith Visa Direct, CoinZoom Instant allows customers to convert their crypto to fiat and send funds to their debit cards.

Key Points: 
  • Through its latest collaboration with Visa to integrate Visa Direct, Visa\'s real-time push payments platform, and participation in the Fintech Fast Track program, the company is launching an innovative service for all customers, called CoinZoom Instant.\nWith Visa Direct, CoinZoom Instant allows customers to convert their crypto to fiat and send funds to their debit cards.
  • "\n"By joining Visa\'s Fast Track program, exciting Fintechs like CoinZoom gain unprecedented access to Visa experts, technology, and resources," said Terry Angelos, SVP and Global Head of Fintech, Visa.
  • "\nVisa\'s Fintech Fast Track Program provides startups like CoinZoom the ability to access Visa\'s growing partner network, and experts who can provide guidance in helping them get up and running in the most efficient way possible.
  • Learn more about Visa\'s Fintech Fast Track program at https://Partner.Visa.com .\n2.

Proposed Dual-Listing on Nasdaq

Friday, May 14, 2021 - 7:00am

b'GAITHERSBURG, Md., May 14, 2021 /PRNewswire/ --MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider of platform technologies for cell engineering, today announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "Offering").\nThe number of securities to be offered and the price for the proposed Offering have not yet been determined.

Key Points: 
  • b'GAITHERSBURG, Md., May 14, 2021 /PRNewswire/ --MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider of platform technologies for cell engineering, today announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "Offering").\nThe number of securities to be offered and the price for the proposed Offering have not yet been determined.
  • The Offering is expected to commence after the SEC completes its review process, subject to market and other conditions, and shareholders and potential investors should note that the proposed Offering may or may not proceed.\nThis press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the "Securities Act").
  • MaxCyte\'s existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research.
  • MaxCyte has granted 12 strategic platform licences to commercial cell therapy developers.

DGAP-News: ENCAVIS AG

Friday, May 14, 2021 - 7:00am

This will also be offered again as scrip dividend in shares or for cash distribution.\nEncavis AG (Prime Standard; ISIN: DE0006095003; ticker symbol: ECV) is a producer of electricity from renewable energies listed on the MDAX of Deutsche B\xc3\xb6rse AG.

Key Points: 
  • This will also be offered again as scrip dividend in shares or for cash distribution.\nEncavis AG (Prime Standard; ISIN: DE0006095003; ticker symbol: ECV) is a producer of electricity from renewable energies listed on the MDAX of Deutsche B\xc3\xb6rse AG.
  • The Encavis Group\'s total generation capacity is currently around 2.8 gigawatts (GW), corresponding to a CO2 avoidance of 1.26 million tonnes p.a.
  • Within the Encavis Group, Encavis Asset Management AG offers fund services to institutional investors.\nENCAVIS is a signatory of the UN Global Compact as well as of the UN PRI network.
  • Encavis AG\'s environmental, social and governance performance has been awarded by two of the world\'s leading ESG rating agencies.

UnionPay Acceptance Enabled for 3,000+ Overseas Online Merchants in 2021 with Russia's Largest E-commerce Platform Now on Board

Friday, May 14, 2021 - 5:46am

b'MOSCOW, May 14, 2021 /PRNewswire/ -- UnionPay International (UPI) announced today that Ozon, Russia\'s largest e-commerce platform, has enabled UnionPay online payment, offering convenient services to 3.3 million cardholders in the country.

Key Points: 
  • b'MOSCOW, May 14, 2021 /PRNewswire/ -- UnionPay International (UPI) announced today that Ozon, Russia\'s largest e-commerce platform, has enabled UnionPay online payment, offering convenient services to 3.3 million cardholders in the country.
  • As a result, the online transaction volume generated by UnionPay cards issued outside Mainland China has been constantly rising.
  • Recently, BPAY, the largest bill payment platform in Australia, and HBLPay, one of the largest e-wallets in Pakistan, have started to accept UnionPay\'s online payments.
  • So far, UnionPay cardholders can pay in installments at around 30,000 merchants such as cross-border e-retailers, academic institutions and airlines.

Praxis Precision Medicines Prices Public Offering of Common Stock

Friday, May 14, 2021 - 3:39am

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.25 per share.
  • The gross proceeds to Praxis from the offering are expected to be approximately $91.25 million, before deducting the underwriting discounts and commissions and other offering expenses.
  • Praxis has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock.\nAll shares in the offering are to be sold by Praxis.
  • The public offering is being made by Praxis only by means of a prospectus relating to the offering.

PureCycle Technologies, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Friday, May 14, 2021 - 3:08am

b'Investors with losses are encouraged to contact the firm before July 12, 2021; click here to submit trade information\n\xe2\x80\x8bLOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of PureCycle Technologies, Inc. (NASDAQ: PCT) investors that acquired shares between November 16, 2020 and May 5, 2021.

Key Points: 
  • b'Investors with losses are encouraged to contact the firm before July 12, 2021; click here to submit trade information\n\xe2\x80\x8bLOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of PureCycle Technologies, Inc. (NASDAQ: PCT) investors that acquired shares between November 16, 2020 and May 5, 2021.
  • If you wish to serve as lead plaintiff, you must move the Court no later than July 12, 2021.\nPlease visit our website to review more information and submit your transaction information.\nThe Portnoy Law Firm represents investors in pursuing arising from corporate wrongdoing.
  • The Firm\xe2\x80\x99s founding partner has recovered over $5.5 billion for aggrieved investors.
  • Prior results do not guarantee similar outcomes.\n'

MultiPlan Corporation Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Friday, May 14, 2021 - 2:30am

b'Investors with over $720 in losses are encouraged to contact the firm before April 26, 2021; click here to submit trade information\nLOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of MultiPlan Corporation (NYSE: MPLN) investors that acquired shares between July 12, 2020 and November 10, 2020.

Key Points: 
  • b'Investors with over $720 in losses are encouraged to contact the firm before April 26, 2021; click here to submit trade information\nLOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of MultiPlan Corporation (NYSE: MPLN) investors that acquired shares between July 12, 2020 and November 10, 2020.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2021.\nPlease visit our website to review more information and submit your transaction information.\nThe Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing.
  • The Firm\xe2\x80\x99s founding partner has recovered over $5.5 billion for aggrieved investors.
  • Prior results do not guarantee similar outcomes.\n'

Fortress Biotech, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Friday, May 14, 2021 - 2:26am

b'Investors with losses are encouraged to contact the firm before January 26, 2021; click here to submit trade information\n\xe2\x80\x8b\xef\xbb\xbfLOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Fortress Biotech, Inc. (NASDAQ: FBIO) investors that acquired shares between December 11, 2019 through October 9, 2020.

Key Points: 
  • b'Investors with losses are encouraged to contact the firm before January 26, 2021; click here to submit trade information\n\xe2\x80\x8b\xef\xbb\xbfLOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Fortress Biotech, Inc. (NASDAQ: FBIO) investors that acquired shares between December 11, 2019 through October 9, 2020.
  • If you wish to serve as lead plaintiff, you must move the Court no later than January 26, 2021.\nPlease visit our website to review more information and submit your transaction information.\nThe Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing.
  • The Firm\xe2\x80\x99s founding partner has recovered over $5.5 billion for aggrieved investors.
  • Prior results do not guarantee similar outcomes.\n'

Digital Brands Group, Inc. Announces Pricing of $10.0 Million Initial Public Offering and Nasdaq Listing

Friday, May 14, 2021 - 1:58am

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.

Key Points: 
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 361,445 shares and 361,445 warrants at the public offering price less the underwriting discounts and commissions.
  • Manatt, Phelps & Phillips, LLP represented Digital Brands and Nelson Mullins Riley & Scarborough LLP acted for Kingswood.\nThe Securities and Exchange Commission ("SEC") declared effective a registration statement on Form S-1 (File No.
  • The Company has strategically expanded into an omnichannel brand offering these styles and content not only on-line but at selected wholesale and retail storefronts.
  • No assurance can be given that the offering will be completed on the terms described, or at all.